Stemline Therapeutics clears first cohort of patients in ongoing SL-801 phase 1 trial
Stemline Therapeutics announced it completed the initial dosing cohort in its SL-801 Phase 1 advanced solid tumor trial. The second cohort is currently open. SL-801 is a novel, oral, small molecule that reversibly inhibits the XPO1 nuclear transport protein active in a wide variety of cancer types. May 03, 2016